

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <b>( Not for submission under 37 CFR 1.99)</b>	Application Number	10567801
	Filing Date	2006-02-09
	First Named Inventor	Bennett
	Art Unit	
	Examiner Name	Not yet assigned
	Attorney Docket Number	101181-1P US

U.S.PATENTS						<input type="button" value="Remove"/>
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	3706810		1972-12-19	American Cyanamid Company	
	2	4599198		1986-07-08	Pfizer Inc.	
	3	4668769		1987-05-26	Dennis J. Hoover	
	4	4692522		1987-09-08	Merck & Co., Inc.	
	5	4720503		1988-01-19	Merck & Co., Inc.	
	6	4751231		1988-06-14	Merck & Co., Inc.	
	7	4786641		1988-11-22	Bayer Aktiengesellschaft	
	8	4794120		1988-12-27	Synthelabo	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>		Application Number		10567801		
		Filing Date		2006-02-09		
		First Named Inventor		Bennett		
		Art Unit				
		Examiner Name		Not yet assigned		
		Attorney Docket Number		101181-1P US		

	9	5863903		1999-01-26	Novo Nordisk A/S	
	10	5998463		1999-12-07	Pfizer Inc.	

If you wish to add additional U.S. Patent citation information please click the Add button.

**U.S.PATENT APPLICATION PUBLICATIONS**

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

**FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	200740	DD	A	1983-06-08	Karl Gewald et. al.		<input checked="" type="checkbox"/>
	2	4445968	DE	A1	1996-06-27	Bayer AG		<input checked="" type="checkbox"/>
	3	0697403	EP	A1	1996-02-21	Sanofi		<input checked="" type="checkbox"/>
	4	0846464	EP	A2	1998-06-10	Pfizer Inc		<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)			Application Number		10567801		
			Filing Date		2006-02-09		
			First Named Inventor		Bennett		
			Art Unit				
			Examiner Name		Not yet assigned		
			Attorney Docket Number			101181-1P US	

	5	0884050	EP	A1	1998-12-16	Novo Nordisk A/S		<input type="checkbox"/>
	6	0978279	EP	A1	2000-02-09	Pfizer Products Inc.		<input type="checkbox"/>
	7	1088824	EP	A2	2001-04-04	Pfizer Products Inc.		<input type="checkbox"/>
	8	1125580	EP	A2	2001-08-22	Pfizer Products Inc.		<input type="checkbox"/>
	9	1134213	EP	A2	2001-09-19	Pfizer Inc.		<input type="checkbox"/>
	10	1136071	EP	A2	2001-09-26	Pfizer Products Inc.		<input type="checkbox"/>
	11	1145717	EP	A2	2001-10-17	Pfizer Products Inc.		<input type="checkbox"/>
	12	1149580	EP	A1	2001-10-31	Pfizer Products Inc.		<input type="checkbox"/>
	13	1177791	EP	A2	2002-02-06	Pfizer Products Inc.		<input type="checkbox"/>
	14	1340500	EP	A1	2003-09-03	Pfizer Products Inc		<input type="checkbox"/>
	15	2081747	ES	A1	1996-03-01	Laboratories del Dr. Esteve, S.A.		<input checked="" type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)			Application Number		10567801		
			Filing Date		2006-02-09		
			First Named Inventor		Bennett		
			Art Unit				
			Examiner Name		Not yet assigned		
			Attorney Docket Number			101181-1P US	

	16	04179949	JP	A	1992-06-26	Fuji Photo Film CO., Ltd.		<input checked="" type="checkbox"/>
	17	2001 089368	JP	A	2001-04-03	Tanabe Seiyaku Co., Ltd		<input checked="" type="checkbox"/>
	18	2001 206856	JP	A	2001-07-31	Pfizer Products Inc.		<input checked="" type="checkbox"/>
	19	2001 247565	JP	A	2001-09-11	Pfizer Products Inc		<input checked="" type="checkbox"/>
	20	2004 196702	JP	A	2004-07-15	Yamanouchi Pharmaceuticals Co., Ltd.		<input checked="" type="checkbox"/>
	21	93/25574	WO	A1	1993-12-23	Pfizer Inc.		<input type="checkbox"/>
	22	95/24391	WO	A1	1995-09-14	Novo Nordisk A/S		<input type="checkbox"/>
	23	96/39384	WO	A1	1996-12-12	Pfizer Inc.		<input type="checkbox"/>
	24	96/39385	WO	A1	1996-12-12	Pfizer Inc.		<input type="checkbox"/>
	25	97/09040	WO	A1	1997-03-13	Novo Nordisk		<input type="checkbox"/>
	26	97/31901	WO	A1	1997-09-04	Mikael Bols		<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)			Application Number		10567801		
			Filing Date		2006-02-09		
			First Named Inventor		Bennett		
			Art Unit				
			Examiner Name		Not yet assigned		
			Attorney Docket Number			101181-1P US	

	27	97/45425	WO	A1	1997-12-04	Fujisawa Pharmaceutical Co., Ltd.		<input type="checkbox"/>
	28	98/27108	WO	A2	1998-06-25	Fujisawa Pharmaceutical Co., Ltd.		<input type="checkbox"/>
	29	98/40353	WO	A1	1998-09-17	Novo Nordisk A/S		<input type="checkbox"/>
	30	98/50359	WO	A1	1998-11-12	Novo Nordisk A/S		<input type="checkbox"/>
	31	99/26659	WO	A1	1999-06-03	Pfizer Products Inc.		<input type="checkbox"/>
	32	99/36393	WO	A1	1999-07-22	Tanabe Seiyaku Co., Ltd.		<input type="checkbox"/>
	33	00/42213	WO	A1	2000-07-20	The Research Foundation of State University of NY		<input type="checkbox"/>
	34	00/47206	WO	A1	2000-08-17	Novo Nordisk A/S		<input type="checkbox"/>
	35	01/05954	WO	A1	2001-01-25	Isis Pharmaceuticals Inc		<input type="checkbox"/>
	36	01/23347	WO	A1	2001-04-05	Novo Nordisk A/S		<input type="checkbox"/>
	37	01/32622	WO	A1	2001-05-10	AstraZeneca AB		<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)			Application Number		10567801		
			Filing Date		2006-02-09		
			First Named Inventor		Bennett		
			Art Unit				
			Examiner Name		Not yet assigned		
			Attorney Docket Number			101181-1P US	

	38	01/32654	WO	A2	2001-05-10	Societe de Conseils de Recherches et D'App Sci		<input checked="" type="checkbox"/>
	39	01/52825	WO	A2	2001-07-26	Novartis AG		<input type="checkbox"/>
	40	01/68055	WO	A1	2001-09-20	Pfizer Products Inc.		<input type="checkbox"/>
	41	01/68092	WO	A2	2001-09-20	Pfizer Products Inc.		<input type="checkbox"/>
	42	01/68603	WO	A2	2001-09-20	Bristol-Myers Squibb Co.		<input type="checkbox"/>
	43	01/94300	WO	A1	2001-12-13	Aventis Pharma Deutschland GMBH		<input checked="" type="checkbox"/>
	44	01/96311	WO	A2	2001-12-20	Bristol-Myers Squibb Company		<input type="checkbox"/>
	45	01/96347	WO	A1	2001-12-20	Bristol-Myers Squibb Company		<input type="checkbox"/>
	46	02/20530	WO	A1	2002-03-14	AstraZeneca AB		<input type="checkbox"/>
	47	02/26714	WO	A1	2002-04-04	Takeda Chemical Industries		<input checked="" type="checkbox"/>
	48	02/34718	WO	A1	2002-05-02	Richter Gedeon Vegyeszeti Gyar RT		<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10567801	
	Filing Date		2006-02-09	
	First Named Inventor		Bennett	
	Art Unit			
	Examiner Name		Not yet assigned	
	Attorney Docket Number		101181-1P US	

	49	02/36583	WO	A1	2002-05-10	Shionogi & Co., Ltd.	<input checked="" type="checkbox"/>
	50	02/80844	WO	A2	2002-10-17	Genzyme Corporation	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	CROCHET R.A., et al., J. Het. Chem., "Synthesis of Substituted Thieno[2,3-b] pyrroles," April 1974, 143-150, Vol. 11.	<input type="checkbox"/>
	2	HARTMAN G.D., et al., "The Synthesis of 5-Alkylaminomethylthieno[2,3-b]Pyrrole-5-Sulfonamides," Heterocycles, 1989, 1943-1949, Vol. 29(10).	<input type="checkbox"/>
	3	MCCORMACK J.G., et al., "Pharmacological Approaches to Inhibit Endogenous Glucose Production as a Means of Anti-diabetic Therapy," Curr. Pharmaceutical Design, 2001, 1451-1474, Vol. 7.	<input type="checkbox"/>
	4	JAKOBSEN P., et al., "Iminosugars: Potential Inhibitors of Liver Glycogen Phosphorylase," Bioorganic Med. Chem., 2001, 733-744, Vol. 9.	<input type="checkbox"/>
	5	TREADWAY J.L., et al., "Glycogen phosphorlase inhibitors for treatment of type 2 diabetes mellitus," Exp. Opin. Invest. Drugs, 2001, 439-454, Vol. 10(3).	<input type="checkbox"/>
	6	RATH V.L. et al., "Activation of Human Liver Glycogen Phosphorylase by Alteration of the Secondary Structure and Packing of the Catalytic Core," Mol. Cell, July 2000, 139-148, Vol. 6.	<input type="checkbox"/>
	7	OIKONOMAKOS N.G., et al., "Allosteric inhibition of glycogen phosphorylase a by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6-tricarboxylate," Protein Sci., 1999, 1930-1945, Vol. 8.	<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>	Application Number		10567801
	Filing Date		2006-02-09
	First Named Inventor		Bennett
	Art Unit		
	Examiner Name		Not yet assigned
	Attorney Docket Number		101181-1P US

8	VENKATARANGAN P., et al., "Prediction of Ligand-Receptor Binding Thermodynamics by Free Energy Force Field Three-Dimensional Quantitative Structure-Activity Relationship Analysis: Applications to a Set of Glucose Analogue Inhibitors of Glycogen Phosphorylase," <i>J. Med. Chem.</i> , 1999, 2169-2179, Vol. 42.	<input type="checkbox"/>
9	HOOVER D.J., et al., "Indole-2-carboxamide Inhibitors of Human Liver Glycogen Phosphorylase," <i>J. Med. Chem.</i> , 1998, 2934-2938, Vol. 41.	<input type="checkbox"/>
10	MARTIN W.H., et al., "Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo," <i>PNAS</i> , Feb. 1998, 1776-1781, Vol. 95.	<input type="checkbox"/>
11	SOMAN G., et al., "The Nature of the Binding Site for Aromatic Compounds in Glycogen Phosphorylase b," <i>Biochem. J.</i> , 1975, 369-371, Vol. 147.	<input type="checkbox"/>
12	SOMAN G., et al. "Aromatic Compounds as Allosteric Inhibitors of Glycogen Phosphorylase b," <i>Biochimica et Biophysica Acta</i> , 1974, 359-362, Vol. 358.	<input type="checkbox"/>
13	ROSAUER K.G., et al., "Novel 3,4-Dihydroquinolin-2(1H)-one Inhibitors of Human Glycogen Phosphorylase a," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 2003, 4385-4388, Vol. 13.	<input type="checkbox"/>
14	TEAGUE J. et al., "Mobilisation of Tissue Glycogen Following Inhibition of Glycogen Phosphorylase in fa/fa Rat," <i>Diabetes</i> , 53, Supp. 2, 2004, A365, 1521-P.	<input type="checkbox"/>
15	VERTIGAN H. et al., "Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents," <i>Diabetologia</i> , 2004, A214, 589, Vol. 47, Supp.1.	<input type="checkbox"/>
16	FONT M. et al. "Indoles and pyridazino[4,5-b]indoles as nonnucleoside analog inhibitors of HIV-1 reverse transcriptase", <i>European Journal Med Chem</i> , 1995, 963-71, Vol. 30.	<input type="checkbox"/>
17	LIN T. et al. "Effects of Protein Binding and Experimental Disease States on Brain Uptake of Benzodiazepines in Rats", <i>J Pharmacology &amp; Eptl Therapeutics</i> , 1990, 45-50, Vol. 253(1).	<input type="checkbox"/>
18	VARNAVAS A. et al. "Quinolone Derivatives: Synthesis and Binding Evaluation on Cholecystokinin Receptors", <i>Il Farmaco</i> , 1996, 341-350, Vol. 51(5).	<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>	Application Number		10567801
	Filing Date		2006-02-09
	First Named Inventor		Bennett
	Art Unit		
	Examiner Name		Not yet assigned
	Attorney Docket Number		101181-1P US

	19	PARSONS W H. et al. "Cholecystokinin Antagonists. Synthesis and Biological Evaluation of 3-Substituted Benzolactams", J Med Chem, 1989, 1681-5, Vol. 32.	<input type="checkbox"/>
	20	FREEMAN S., et al., "Effect of Glucose on Rat and Human Liver Glycogen Phosphorylase Activity and Potency of a Glycogen Phosphorylase Inhibitor," Diabetes, 52, Supp., 2003, A340, 1470-P.	<input type="checkbox"/>
	21	TURNBULL A., et al., "Pharmacological Inhibition of Glycogen Phosphorylase (GP) Lowers Plasma Glucose in Rat Models of Type 2 Diabetes," Diabetes, 52, Supp., 2003, A343, 1485-P.	<input type="checkbox"/>
	22	BIRCH A., et al., "Novel Thienopyrrole Glycogen Phosphorylase Inhibitors: In Vitro SAR and Crystallographic Studies," Poster, Cambridge Med Chem Symposium, Sept 2003.	<input type="checkbox"/>
	23	HUDSON S., et al., "The effect of a glycogen phosphorylase inhibitor upon muscle fatigue in anaesthetised rats," J. Physiol., 2002, 52-53, Vol. 539.	<input type="checkbox"/>
	24	VERTIGAN H. et al., "Impact of cell glycogen content on modulation of hepatocyte glucose metabolism by pharmacological agents", EASD Munich, 2004.	<input type="checkbox"/>
	25	BARTLETT J. et al., "In Vitro and In Vivo Profile of Gpi688, a Novel, Potent Inhibitor of Glycogen Phosphorylase", ADA San Diego, 2005.	<input type="checkbox"/>
	26	BENNETT S N L. et al., "Novel Orally Active Amino-indan Inhibitors of Glycogen Phosphorylase", Cambridge Med Chem Conference, Sept 2005. Poster EOM.	<input type="checkbox"/>
	27	GREEN A R. et al., "The Glycogenic Action of Protein Targeting to Glycogen in Hepatocytes Involves Multiple Mechanisms Including Phosphorylase Inactivation and Glycogen Synthase Translocation", J Biol Chem, 2004, 46474-46482, Vol. 279(45).	<input type="checkbox"/>
	28	ROBERTS P A. et al., "The temporal relationship between glycogen phosphorylase and activation of the pyruvate dehydrogenase complex during adrenaline infusion in resting canine skeletal muscle", J Physiology, 2002, 297-304, Vol. 545(1).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <b>( Not for submission under 37 CFR 1.99)</b>	Application Number	10567801
	Filing Date	2006-02-09
	First Named Inventor	Bennett
	Art Unit	
	Examiner Name	Not yet assigned
	Attorney Docket Number	101181-1P US

### EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <b>( Not for submission under 37 CFR 1.99)</b>	Application Number		10567801
	Filing Date		2006-02-09
	First Named Inventor		Bennett
	Art Unit		
	Examiner Name		Not yet assigned
	Attorney Docket Number		101181-1P US

### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

**OR**

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

See attached certification statement.  
 Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.  
 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Lucy Padget/	Date (YYYY-MM-DD)	2006-06-12
Name/Print	Lucy Padget Registration No: L0074	Registration Number	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.